Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriers

Journal of Bone and Mineral Research

Volumn 28, Issue 4, 2013, Pages 848-854

  Van Lierop, Antoon H ^a   Hamdy, Neveen A T ^a   Van Egmond, Martje E ^b   Bakker, Egbert ^a   Dikkers, Freek G ^b   Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

bone formation; bone mineral density; bone resorption; sclerostin; Van Buchem disease

Indexed keywords

COLLAGEN TYPE 1; PROTEIN PRECURSOR; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; GENETIC MARKER; PEPTIDE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE; SOST PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE DYSPLASIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CARRIER; DISEASE COURSE; FACIAL NERVE PARALYSIS; FEMALE; FEMUR NECK; GENE MUTATION; HEARING IMPAIRMENT; HETEROZYGOTE; HUMAN; INTRACRANIAL HYPERTENSION; MALE; OSSIFICATION; OSTEOSCLEROSIS; PHENOTYPE; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; SPINE; VAN BUCHEM DISEASE; BLOOD; CASE CONTROL STUDY; CHONDRODYSPLASIA; DENSITOMETRY; GENETIC MARKER; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY;

ADULT; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CASE-CONTROL STUDIES; COLLAGEN TYPE I; DENSITOMETRY; FEMALE; GENETIC MARKERS; HETEROZYGOTE; HUMANS; MALE; OSTEOCHONDRODYSPLASIAS; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN;

EID: 84875343487     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1794     Document Type: Article

References (31)

1. Van Buchem FS, Hadders HN, Ubbens R., An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol. 1955; 44: 109-20.
2. Van Buchem FS, Hadders HN, Hansen JF, Woldring MG., Hyperostosis corticalis generalisata. Report of seven cases. Am J Med. 1962; 33: 387-97.
3. Van Buchem FS, Hyperostosis corticalis., generalisata Eight new cases. Acta Med Scand. 1971; 189: 257-67.
4. Beighton P, Durr L, Hamersma H., The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals. Ann Intern Med. 1976; 4: 393-7.
5. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW., Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004; 199: 805-14.
6. Brunkow ME, Gardner JC, Van NJ, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J., Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68: 577-89.
7. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W., Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10: 537-43.
8. Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H, Brunkow ME., A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002; 110: 144-52.
9. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W., Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002; 39: 91-7.
10. Hamersma H, Gardner J, Beighton P., The natural history of sclerosteosis. Clin Genet. 2003; 63: 192-7.
11. van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE., Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011; 26: 2804-11.
12. Beighton P, Barnard A, Hamersma H, van der Wouden A., The syndromic status of sclerosteosis and van Buchem disease. Clin Genet. 1984; 25: 175-81.
13. van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE., Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol. 2010; 163: 833-7.
14. van Lierop AH, Hamdy NA, Papapoulos SE., Glucocorticoids are not always deleterious for bone. J Bone Miner Res. 2010; 25: 2796-800.
15. van Egmond ME, Dikkers FG, Boot AM, van Lierop AH, Papapoulos SE, Brouwer OF., A rare cause of facial nerve palsy in children: hyperostosis corticalis generalisata (Van Buchem disease). Three new pediatric cases and a literature review. Eur J Paediatr Neurol. 2012 Nov; 16 (6): 740-3.
16. Fosmoe RJ, Holm RS, Hildreth RC., Van Buchem's disease (hyperostosis corticalis generalisata familiaris). A case report. Radiology. 1968; 90: 771-4.
17. Schendel SA., Van Buchem disease: surgical treatment of the mandible. Ann Plast Surg. 1988; 20: 462-7.
18. Dixon JM, Cull RE, Gamble P., Two cases of Van Buchem's disease. J Neurol Neurosurg Psychiatry. 1982; 45: 913-8.
19. Dyson DP., Van Buchem's disease (hyperostosis corticalis generalisata familiaris). A case report. Br J Oral Surg. 1972; 9: 237-45.
20. Jacobs P., Van Buchem disease. Postgrad Med J. 1977; 53: 497-506.
21. Scopelliti D, Orsini R, Ventucci E, Carratelli D., Van Buchem disease. Maxillofacial changes, diagnostic classification and general principles of treatment. Minerva Stomatol. 1999; 48: 227-34.
22. Van Hul W, Balemans W, Van Hul E, Dikkers FG, Obee H, Stokroos RJ, Hildering P, Vanhoenacker F, Van Camp G, Willems PJ., Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21. Am J Hum Genet. 1998; 62: 391-9.
23. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Bénichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W., Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet. 2003; 72: 763-71.
24. Wengenroth M, Vasvari G, Federspil PA, Mair J, Schneider P, Stippich C., Case 150: Van Buchem disease (hyperostosis corticalis generalisata). Radiology. 2009; 253: 272-6.
25. Vanhoenacker FM, Balemans W, Tan GJ, Dikkers FG, De Schepper AM, Mathysen DG, Bernaerts A, Hul WV., Van Buchem disease: lifetime evolution of radioclinical features. Skeletal Radiol. 2003; 32: 708-18.
26. du Plessis JJ., Sclerosteosis: neurosurgical experience with 14 cases. J Neurosurg. 1993; 78: 388-92.
27. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM., Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005; 15: 928-35.
28. van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, Wee-Pals L, Balemans W, Oostenbroek HJ, Van HW, Hamersma H, Dikkers FG, Hamdy NA, Papapoulos SE, Lowik CW., Sclerostin in mineralized matrices and van Buchem disease. J Dent Res. 2009; 88: 569-74.
29. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA., Osteocyte control of bone formation via sclerostin a novel BMP antagonist. EMBO J. 2003; 22: 6267-76.
30. Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA, Lowik CW, Hamersma H, Beighton P, Papapoulos SE., Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab. 2005; 90: 6392-5.
31. Padhi D, Jang G, Stouch B, Fang L, Posvar E., Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26: 19-26.